News

With this acquisition, Atrium will take over a manufacturing plant and process that is approved by different regulatory bodies in countries where Wobenzym products are sold. Atrium distributes

The projects – aimed at treating conditions such as vision loss, neurodegenerative disease and depression – are funded through the NIH Blueprint for Neuroscience Research. The NIH Blueprint

Furiex will use the loan to support research and development for clinical stage compounds JNJ-Q2, MuDelta and PPD10558. Furiex Pharmaceuticals chief financial officer, treasurer and assistant secretary Marshall

The company informed that at a median of 17 months follow-up, the relapse rate in patients with low levels of HER2 expression treated with AE37 is half that

Focalin is used in the treatment of attention deficit hyperactivity disorder (ADHD). Intellipharmaceutics will receive a cash amount from Par and will continue to obtain a share of

Vecuronium bromide for injection is indicated for the patients with myasthenia gravis or the myasthenic (Eaton-Lambert) syndrome (muscle weakness/fatigue). The injection features Sagent’s PreventIV Measures packaging and labeling

The results from Phase 2b study suggested that lasmiditan achieved its primary endpoint of reducing a moderate or severe headache at baseline to mild or none 2 hours

The company has previously released positive results from a Phase II (DTCL100) trial evaluating KRN5500, which demonstrated reduction of pain and safety and was superior to placebo. Based

The filing includes chemistry, manufacturing and controls (CMC) section of NDA for Gattex, which is indicated for the treatment of adults suffering from short bowel syndrome (SBS). Previously,